|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E mutation) negatively affect response to anti-epidermal growth factor receptor (EGFR) mAbs in metastatic colorectal cancer (mCRC) patients, while the biological impact of the EGFR pathway represented by PI3K/PTEN/AKT on anti-EGFR treatment is still not clear.
|
18669866 |
2009 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It has been reported that KRAS mutations (and to a lesser extent KRAS mutations with the BRAF V600E mutation) negatively affect response to anti-epidermal growth factor receptor (EGFR) mAbs in metastatic colorectal cancer (mCRC) patients, while the biological impact of the EGFR pathway represented by PI3K/PTEN/AKT on anti-EGFR treatment is still not clear.
|
18669866 |
2009 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Primary tumours from 144 patients treated for mCRC were assessed for BRAF (V600E) mutation, MSI status and cyclin D1.
|
20485284 |
2010 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Primary tumours from 144 patients treated for mCRC were assessed for BRAF (V600E) mutation, MSI status and cyclin D1.
|
20485284 |
2010 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.
|
21289333 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, 239 samples obtained from 215 patients with metastatic colorectal cancer were tested for the presence of the seven most common mutations in the KRAS gene and the V600E mutation in the BRAF gene.
|
20645028 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis provides evidence that BRAF V600E mutation is associated with lack of response in wild-type KRAS mCRC treated with anti-EGFR MoAbs.
|
20857202 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future metastatic colorectal cancer genotyping might also include the detection of the BRAF V600E mutation, which is a very strong negative prognostic factor in colorectal cancer.
|
21516079 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future metastatic colorectal cancer genotyping might also include the detection of the BRAF V600E mutation, which is a very strong negative prognostic factor in colorectal cancer.
|
21516079 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, 239 samples obtained from 215 patients with metastatic colorectal cancer were tested for the presence of the seven most common mutations in the KRAS gene and the V600E mutation in the BRAF gene.
|
20645028 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.
|
21289333 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis provides evidence that BRAF V600E mutation is associated with lack of response in wild-type KRAS mCRC treated with anti-EGFR MoAbs.
|
20857202 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study we described the KRAS and the BRAF V600E mutation spectra and frequencies in a group of Serbian mCRC specimens.
|
23033302 |
2012 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study we described the KRAS and the BRAF V600E mutation spectra and frequencies in a group of Serbian mCRC specimens.
|
23033302 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inadequate evidence was found regarding association of BRAF V600E mutation testing or loss of PTEN expression with improved health outcomes among patients with mCRC undergoing anti-EGFR therapy as compared with patients with tumors bearing wild-type BRAF sequence and PTEN expression levels, respectively.
|
23429431 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Inadequate evidence was found regarding association of BRAF V600E mutation testing or loss of PTEN expression with improved health outcomes among patients with mCRC undergoing anti-EGFR therapy as compared with patients with tumors bearing wild-type BRAF sequence and PTEN expression levels, respectively.
|
23429431 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Since RAC1b has been associated with the BRAF(V600E) mutation, associated with poor prognosis in CRC, we evaluated the role of RAC1b expression as a predictor of chemotherapy efficacy in mCRC.
|
24833563 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We describe survival outcomes and the impact of chemotherapy, metastatectomy, and BRAF V600E mutation status in the largest reported cohort of MSI-H metastatic colorectal cancer (CRC).
|
24585723 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
By calculating the ΔC q for real-time traditional PCR, which amplifies all BRAF alleles, versus WTB-PCR, which selectively amplifies mutant BRAF, we demonstrated that among the V600E-positive mCRC patient samples, the percentage of BRAF DNA with the V600E mutation ranged from 0.05 to 52.32%.
|
24500755 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
IHC using the VE1 clone is a specific and sensitive method for the detection of BRAF(V600E) and may be either a complementary or an alternative method to molecular testing in mCRC patients.
|
24798160 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we report the first clinical evidence that the combination of an anti-EGFR (panitumumab) and an inhibitor of BRAF(V600E) (vemurafenib) is well tolerated and results in a strong disease control in an extensively pretreated mCRC patient.
|
24755613 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation plays a negative prognostic role in metastatic colorectal cancer (mCRC), leading to a median Progression Free Survival (PFS) of 4-6months with first-line conventional treatments.
|
24138831 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study aimed to evaluate the relationship between BRAF V600E mutation and the tumor response of anti-EGFR MoAbs for first-line treatment in mCRC patients.
|
24390240 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we report the first clinical evidence that the combination of an anti-EGFR (panitumumab) and an inhibitor of BRAF(V600E) (vemurafenib) is well tolerated and results in a strong disease control in an extensively pretreated mCRC patient.
|
24755613 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
By calculating the ΔC q for real-time traditional PCR, which amplifies all BRAF alleles, versus WTB-PCR, which selectively amplifies mutant BRAF, we demonstrated that among the V600E-positive mCRC patient samples, the percentage of BRAF DNA with the V600E mutation ranged from 0.05 to 52.32%.
|
24500755 |
2014 |